You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

5191 Results
Document
Jun 2019
Document
Jun 2019
Document
Jun 2019
Document
Jun 2019
Document
Jun 2019
Document
Jun 2019
Document
Jun 2019
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Bortezomib - In Combination with Selinexor and Dexamethasone for Previously Treated Multiple Myeloma
ODB - General Benefit
    dexamethasone
Exceptional Access Program
    selinexor - In combination with bortezomib and dexamethasone for relapsed or refractory multiple myeloma
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
bortezomib,
dexamethasone,
selinexor
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Nov 2024
Document
Jun 2019
Document
Jun 2019
Drug
Other Name(s): Folotyn®
Quick Link(s): Drug Monograph, Patient Info Sheet
Dec 2021

Pages